2023 Annual Meeting | Industry Therapeutic Update from Novartis: Novel and Prospective Therapies and Biomarkers for Multiple Sclerosis

Date Monday 04/24/23

Time 06:00 PM - 09:00 PM EST Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Jason W. Freeman, MD, Brandon Brown, PharmD

Topic(s) General Neurology, Movement Disorders, Multiple Sclerosis

Learning Objectives Overview of Novartis' commitment to Multiple Sclerosis (MS) that will highlight: (1) long-term safety and efficacy with an anti-CD20 monoclonal antibody, (2) sNfL and other novel biomarkers: changing the paradigm of patient management, (3) development of a novel BTKI in the treatment of multiple sclerosis.

Speakers:
Jason Freeman, MD
Brandon Brown, PharmD
Gina Cox, PhD
Steven Yeung, DO

Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 09:00 PM EST	Speaker	Industry Therapeutic Update from Novartis: Novel and Prospective Therapies and Biomarkers for Multiple Sclerosis

Faculty Disclosures
Jason W. Freeman, MD	Dr. Freeman has received personal compensation for serving as an employee of Novartis . Dr. Freeman has stock in Novartis .
Brandon Brown, PharmD	Dr. Brown has received personal compensation for serving as an employee of Novartis. Dr. Brown has stock in Novartis.